



Synta Pharmaceuticals to Participate in Panel Titled New Targets in Cancer Therapy at the RBC Capital Markets Healthcare Conference

February 23, 2010

Company to Webcast Panel Presentation on March 2

LEXINGTON, Mass., Feb 23, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion titled New Targets in Cancer Therapy at the RBC Capital Markets Healthcare Conference on Tuesday, March 2 at 8:00 am (ET) at The New York Palace Hotel.

A live audio webcast and replay of the panel will be available on the "Investors" section of the Company's website, <http://www.syntapharma.com>.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit <http://www.syntapharma.com>.

SOURCE: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125